JP5702390B2 - タンパク質チロシンキナーゼ２阻害剤としてのピリミジン誘導体 - Google Patents
タンパク質チロシンキナーゼ２阻害剤としてのピリミジン誘導体 Download PDFInfo
- Publication number
- JP5702390B2 JP5702390B2 JP2012531442A JP2012531442A JP5702390B2 JP 5702390 B2 JP5702390 B2 JP 5702390B2 JP 2012531442 A JP2012531442 A JP 2012531442A JP 2012531442 A JP2012531442 A JP 2012531442A JP 5702390 B2 JP5702390 B2 JP 5702390B2
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- independently
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172026.8 | 2009-10-02 | ||
| EP09172026 | 2009-10-02 | ||
| EP10172460.7 | 2010-08-11 | ||
| EP10172460 | 2010-08-11 | ||
| PCT/EP2010/064628 WO2011039344A1 (en) | 2009-10-02 | 2010-10-01 | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013506636A JP2013506636A (ja) | 2013-02-28 |
| JP5702390B2 true JP5702390B2 (ja) | 2015-04-15 |
Family
ID=43048878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012531442A Active JP5702390B2 (ja) | 2009-10-02 | 2010-10-01 | タンパク質チロシンキナーゼ２阻害剤としてのピリミジン誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8466155B2 (enExample) |
| EP (1) | EP2483249B1 (enExample) |
| JP (1) | JP5702390B2 (enExample) |
| KR (1) | KR20120092617A (enExample) |
| CN (1) | CN102695700A (enExample) |
| AP (1) | AP2012006166A0 (enExample) |
| AR (1) | AR078513A1 (enExample) |
| AU (1) | AU2010302648A1 (enExample) |
| BR (1) | BR112012007300A2 (enExample) |
| CA (1) | CA2775418A1 (enExample) |
| CL (1) | CL2012000825A1 (enExample) |
| EA (1) | EA201200552A1 (enExample) |
| EC (1) | ECSP12011830A (enExample) |
| IL (1) | IL218543A0 (enExample) |
| IN (1) | IN2012DN02714A (enExample) |
| MA (1) | MA33606B1 (enExample) |
| MX (1) | MX2012003101A (enExample) |
| NZ (1) | NZ598614A (enExample) |
| PE (1) | PE20121431A1 (enExample) |
| PH (1) | PH12012500527A1 (enExample) |
| TN (1) | TN2012000142A1 (enExample) |
| TW (1) | TW201124386A (enExample) |
| UY (1) | UY32916A (enExample) |
| WO (1) | WO2011039344A1 (enExample) |
| ZA (1) | ZA201201703B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
| WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| EP2832734A4 (en) | 2012-03-28 | 2015-08-26 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CA2949048A1 (en) * | 2013-05-22 | 2014-11-27 | The Regents Of The University Of California | Aurora kinase inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| JP4460292B2 (ja) | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| JP2005526765A (ja) * | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
| AR042486A1 (es) | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
| JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| EP1794134A1 (de) * | 2004-09-29 | 2007-06-13 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| EP1966207A2 (en) | 2005-12-21 | 2008-09-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| GB0619343D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| EP2109605B1 (en) * | 2006-12-22 | 2013-02-20 | Boehringer Ingelheim International GmbH | 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer |
| MX2009011199A (es) | 2007-04-16 | 2010-03-17 | Hutchison Medipharma Entpr Ltd | Derivados de pirimidina. |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
-
2010
- 2010-09-29 US US12/893,240 patent/US8466155B2/en active Active
- 2010-09-30 UY UY0001032916A patent/UY32916A/es not_active Application Discontinuation
- 2010-10-01 AR ARP100103594A patent/AR078513A1/es unknown
- 2010-10-01 PH PH1/2012/500527A patent/PH12012500527A1/en unknown
- 2010-10-01 CA CA2775418A patent/CA2775418A1/en not_active Abandoned
- 2010-10-01 AU AU2010302648A patent/AU2010302648A1/en not_active Abandoned
- 2010-10-01 CN CN201080054924XA patent/CN102695700A/zh active Pending
- 2010-10-01 TW TW099133534A patent/TW201124386A/zh unknown
- 2010-10-01 EA EA201200552A patent/EA201200552A1/ru unknown
- 2010-10-01 IN IN2714DEN2012 patent/IN2012DN02714A/en unknown
- 2010-10-01 AP AP2012006166A patent/AP2012006166A0/xx unknown
- 2010-10-01 BR BR112012007300A patent/BR112012007300A2/pt not_active IP Right Cessation
- 2010-10-01 KR KR1020127011321A patent/KR20120092617A/ko not_active Withdrawn
- 2010-10-01 NZ NZ598614A patent/NZ598614A/xx not_active IP Right Cessation
- 2010-10-01 JP JP2012531442A patent/JP5702390B2/ja active Active
- 2010-10-01 EP EP10759924.3A patent/EP2483249B1/en active Active
- 2010-10-01 WO PCT/EP2010/064628 patent/WO2011039344A1/en not_active Ceased
- 2010-10-01 MX MX2012003101A patent/MX2012003101A/es active IP Right Grant
- 2010-10-01 PE PE2012000420A patent/PE20121431A1/es not_active Application Discontinuation
-
2012
- 2012-03-08 IL IL218543A patent/IL218543A0/en unknown
- 2012-03-08 ZA ZA2012/01703A patent/ZA201201703B/en unknown
- 2012-03-26 MA MA34719A patent/MA33606B1/fr unknown
- 2012-03-29 TN TNP2012000142A patent/TN2012000142A1/en unknown
- 2012-04-02 CL CL2012000825A patent/CL2012000825A1/es unknown
- 2012-04-26 EC ECSP12011830 patent/ECSP12011830A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013506636A (ja) | 2013-02-28 |
| MA33606B1 (fr) | 2012-09-01 |
| ECSP12011830A (es) | 2012-06-29 |
| MX2012003101A (es) | 2012-04-11 |
| AR078513A1 (es) | 2011-11-16 |
| AP2012006166A0 (en) | 2012-04-30 |
| IN2012DN02714A (enExample) | 2015-09-11 |
| TW201124386A (en) | 2011-07-16 |
| TN2012000142A1 (en) | 2013-09-19 |
| PH12012500527A1 (en) | 2012-10-22 |
| BR112012007300A2 (pt) | 2017-11-07 |
| EP2483249A1 (en) | 2012-08-08 |
| UY32916A (es) | 2011-04-29 |
| AU2010302648A1 (en) | 2012-04-05 |
| CL2012000825A1 (es) | 2012-08-24 |
| US20110237598A1 (en) | 2011-09-29 |
| CN102695700A (zh) | 2012-09-26 |
| CA2775418A1 (en) | 2011-04-07 |
| ZA201201703B (en) | 2014-05-28 |
| EP2483249B1 (en) | 2015-12-23 |
| NZ598614A (en) | 2013-08-30 |
| PE20121431A1 (es) | 2012-11-10 |
| US8466155B2 (en) | 2013-06-18 |
| EA201200552A1 (ru) | 2013-03-29 |
| IL218543A0 (en) | 2012-05-31 |
| WO2011039344A1 (en) | 2011-04-07 |
| KR20120092617A (ko) | 2012-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2483249B1 (en) | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors | |
| EP2978757B1 (en) | Indolinone analogues as brd4 inhibitors | |
| AU2013346809B2 (en) | Triazolopyrazine | |
| EP2978758B1 (en) | Dihydroquinazolinone analogues as brd4 inhibitors | |
| EP3066104B1 (en) | Triazolopyrazine derivatives as brd4 inhibitors | |
| EP3140304B1 (en) | Benzimidazole derivatives | |
| EP2571877A1 (en) | 1h - imidazo [4, 5 - c]quinolines | |
| JP2016531126A (ja) | 新規ビスアミドピリジン | |
| US8466162B2 (en) | 5-alkynyl-pyridines | |
| HK1172027A (en) | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140213 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5702390 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |